Evidence map›Paper›PMID 35203394›Full record

ArticleCells2022

Enhanced Autophagic Flux, Suppressed Apoptosis and Reduced Macrophage Infiltration by Dasatinib in Kidneys of Obese Mice.

Hassan Reda Hassan Elsayed, Randa El-Gamal, Mohammed R Rabei, Mona G Elhadidy, Shereen Hamed, Basma H Othman, Mohamed Mahmoud Abdelraheem Elshaer, Mostafa Khaled Sedky, Ahmed Tarek Abd Elbaset Hassan, Mohammad El-Nablaway

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Hassan Reda Hassan ElsayedDepartment of Anatomy and Embryology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0002-3489-3279
Randa El-GamalDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0003-0211-1030
Mohammed R RabeiDepartment of Medical Physiology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mona G ElhadidyDepartment of Medical Physiology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Shereen HamedDepartment of Medical Histology and Cell Biology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.ORCID 0000-0001-8989-0860
Basma H OthmanMedical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mohamed Mahmoud Abdelraheem ElshaerDepartment of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt.
Mostafa Khaled SedkyDepartment of Surgery, Faculty of Medicine, King Salman International University, South Sinai 46511, Egypt.ORCID 0000-0002-8800-9346
Ahmed Tarek Abd Elbaset HassanDepartment of Surgery, Faculty of Medicine, King Salman International University, South Sinai 46511, Egypt.
Mohammad El-NablawayDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mansoura University · EGKing Salman International UniversityAin Shams University · EGAlfaisal University · SADamietta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity causes renal changes (ORC), characterized by defective renal autophagy, lipogenesis, enhanced macrophage infiltration and apoptosis. We hypothesize that Dasatinib, a tyrosine kinase inhibitor, may ameliorate changes associated with obesity. We the mice with either Obesogenic diet (OD) or a standard basal diet. After 12 weeks, the mice received either vehicle or Dasatinib 4 mg/kg/d for an additional four weeks. We examined serum creatinine, urea, lipid profile and renal cortical mRNA expression for lipogenesis marker SREBP1, inflammatory macrophage marker iNOS and fibrosis markers; TGFβ and PDGFA genes; immunohistochemical (IHC) staining for CD68; inflammatory macrophage marker and ASMA; fibrosis marker, LC3 and SQSTM1/P62; autophagy markers and western blotting (WB) for caspase-3; and, as an apoptosis marker, LC3II/I and SQSTM1/P62 in addition to staining for H&E, PAS, Sirius red and histopathological scoring. Dasatinib attenuated renal cortical mRNA expression for SREBP1, iNOS, PDGFA and TGFβ and IHC staining for CD68, ASMA and SQSTM1/P62 and WB for caspase-3 and SQSTM1/P62, while elevating LC3 expression. Moreover, Dasatinib ameliorated ORC; glomerulosclerosis, glomerular expansion, tubular dilatation, vacuolation and casts; inflammatory cellular infiltration; and fibrosis. Dasatinib is a promising therapy for ORC by correcting autophagy impairment, attenuating lipogenesis, apoptosis and macrophage infiltration by inducing antifibrotic activity.

Indexed as

ApoptosisAutophagyAnimalsCaspase 3DasatinibFibrosisKidneyMacrophagesMiceMice, ObeseObesityRNA, MessengerSequestosome-1 ProteinTransforming Growth Factor betaCaspase 3DasatinibRNA, MessengerSequestosome-1 ProteinTransforming Growth Factor betaautophagyDasatinibmacrophagesobesitytyrosine kinase inhibitors

Identifiers

PMID35203394
PMCPMC8869974
OpenAlexW4213113501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.